The Impact of Hispanic Ethnicity and the Titration Effect of LY2189265, a Glucagon-Like Peptide 1 Analog, on Metabolic Outcome Measures in Patients with Uncontrolled Type 2 Diabetes Mellitus (T2DM): An EGO Study Analysis.

被引：0
|
作者：
Bastyr, E. J., III [1 ,2 ]
Cheng, C. L. [1 ]
Noriega, J. E. [1 ,2 ]
Thompson, A. B. [1 ]
Threlkeld, R. J. [1 ]
Shu, J. [3 ]
Glass, L. C. [1 ]
机构：
[1] Lilly Res Labs, Indianapolis, IN USA
[2] Indiana Univ, Sch Med, Indianapolis, IN USA
[3] i3 Statprobe, Ann Arbor, MI USA
来源：
ENDOCRINE REVIEWS | 2010年 / 31卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Impact of Hispanic Ethnicity on the Response to LY2189265(GLP-1 Analog) Treatment of Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients: An EGO Study Analysis
    Bastyr, Edward J., III
    Noriega, Julio
    Botros, Fady T.
    Threlkeld, Rebecca
    Shu, Jianfen
    Anderson, James H., Jr.
    Glass, Leonard C.
    DIABETES, 2010, 59 : A161 - A161
  • [2] THE IMPACT OF LY2189265 (GLP-1 ANALOG) ON GLYCEMIC CONTROL IN HISPANIC AND NON-HISPANIC CAUCASIANS WITH UNCONTROLLED TYPE 2 DIABETES: AN EGO STUDY ANALYSIS
    Noriega, J.
    Botros, F.
    Threlkeld, R.
    Shu, J.
    Anderson, J.
    Glass, L.
    Bastyr, E.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2010, 58 (04) : 644 - 644
  • [3] Reductions in Glycemia and Weight with Once Weekly Dosing of LY2189265, a Long-Acting Glucagon-Like Peptide 1 (GLP-1) Analog in Patients with Type 2 Diabetes Mellitus
    Barrington, Philip
    Hardy, Thomas A.
    Chien, Jenny Y.
    Showalter, H. D. Hollins
    Schneck, Karen B.
    Cui, Sherry
    Tibaldi, Fabian
    Ellis, Bernice
    DIABETES, 2009, 58 : A42 - A42
  • [4] Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
    Fazeli, Sasan
    Ehrhardt, Nicole
    DIABETES, 2018, 67
  • [5] The effect of LY2189265 (GLP-1 analogue) once weekly on HbA1c and beta cell function in uncontrolled type 2 diabetes mellitus: the EGO study analysis
    Umpierrez, G.
    Blevins, T.
    Rosenstock, J.
    Cheng, C.
    Bastyr, E.
    Anderson, J.
    DIABETOLOGIA, 2009, 52 : S59 - S59
  • [6] A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
    Barrington, P.
    Chien, J. Y.
    Showalter, H. D. H.
    Schneck, K.
    Cui, S.
    Tibaldi, F.
    Ellis, B.
    Hardy, T. A.
    DIABETES OBESITY & METABOLISM, 2011, 13 (05): : 426 - 433
  • [7] Reductions in glycaemia and weight with once-weekly dosing of LY2189265, a long-acting glucagon-like peptide 1 (GLP-1) analogue in patients with type 2 diabetes mellitus
    Hardy, T. A.
    Barrington, P.
    Chien, J.
    Showalter, H.
    Schneck, K.
    Cui, S.
    Tibaldi, F.
    Ellis, B.
    DIABETOLOGIA, 2009, 52 : S286 - S286
  • [8] The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
    Umpierrez, G. E.
    Blevins, T.
    Rosenstock, J.
    Cheng, C.
    Anderson, J. H.
    Bastyr, E. J., III
    DIABETES OBESITY & METABOLISM, 2011, 13 (05): : 418 - 425
  • [9] GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN
    Norrbacka, K.
    Sicras-Mainar, A.
    Hernandez, I
    Tofe-Povedano, S.
    Diaz Cerezo, S.
    Artime, E.
    Lebrec, J.
    Romera, I
    VALUE IN HEALTH, 2019, 22 : S594 - S594
  • [10] Adherence to Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Patients with Type 2 Diabetes Mellitus (T2DM)
    Johnston, Stephen
    Nguyen, Hiep
    Felber, Eugene
    Cappell, Katherine
    Nelson, James K.
    Chu, Bong-Chul
    Kalsekar, Iftekhar
    DIABETES, 2014, 63 : A604 - A604
12345